

RESEARCH ARTICLE

# Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial

Sally Chiu, Paul T. Williams, Ronald M. Krauss\*

Children's Hospital Oakland Research Institute, Oakland, California, United States of America

\* [rkrauss@chori.org](mailto:rkrauss@chori.org)



## Abstract

### Background

Previous studies have shown that increases in LDL-cholesterol resulting from substitution of dietary saturated fat for carbohydrate or unsaturated fat are due primarily to increases in large cholesterol-enriched LDL, with minimal changes in small, dense LDL particles and apolipoprotein B. However, individuals can differ by their LDL particle distribution, and it is possible that this may influence LDL subclass response.

### Objective

The objective of this study was to test whether the reported effects of saturated fat apply to individuals with atherogenic dyslipidemia as characterized by a preponderance of small LDL particles (LDL phenotype B).

### Methods

Fifty-three phenotype B men and postmenopausal women consumed a baseline diet (55%E carbohydrate, 15%E protein, 30%E fat, 8%E saturated fat) for 3 weeks, after which they were randomized to either a moderate carbohydrate, very high saturated fat diet (HSF; 39% E carbohydrate, 25%E protein, 36%E fat, 18%E saturated fat) or low saturated fat diet (LSF; 37%E carbohydrate, 25%E protein, 37%E fat, 9%E saturated fat) for 3 weeks.

### Results

Compared to the LSF diet, consumption of the HSF diet resulted in significantly greater increases from baseline (% change; 95% CI) in plasma concentrations of apolipoprotein B (HSF vs. LSF: 9.5; 3.6 to 15.7 vs. -6.8; -11.7 to -1.76;  $p = 0.0003$ ) and medium (8.8; -1.3 to 20.0 vs. -7.3; -15.7 to 2.0;  $p = 0.03$ ), small (6.1; -10.3 to 25.6 vs. -20.8; -32.8 to -6.7;  $p = 0.02$ ), and total LDL (3.6; -3.2 to 11.0 vs. -7.9; -13.9 to -1.5;  $p = 0.03$ ) particles, with no differences in change of large and very small LDL concentrations. As expected, total-cholesterol (11.0; 6.5 to 15.7 vs. -5.7; -9.4 to -1.8;  $p < 0.0001$ ) and LDL-cholesterol (16.7; 7.9 to 26.2 vs. -8.7; -15.4 to -1.4;  $p = 0.0001$ ) also increased with increased saturated fat intake.

## OPEN ACCESS

**Citation:** Chiu S, Williams PT, Krauss RM (2017) Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial. PLoS ONE 12(2): e0170664. doi:10.1371/journal.pone.0170664

**Editor:** Alberico Catapano, Università degli Studi di Milano, ITALY

**Received:** October 14, 2016

**Accepted:** January 8, 2017

**Published:** February 6, 2017

**Copyright:** © 2017 Chiu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** A de-identified minimal data set is included as a Supporting Information file.

**Funding:** This research was funded by Dairy Management Inc and was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views

of the NIH. This was an investigator-initiated study, and its funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** This study was funded by a commercial source, Dairy Management Inc.; however we declare that no competing interests exist, except that Dr. Krauss has also received research grant support from the Almond Board of California. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

## Conclusions

Because medium and small LDL particles are more highly associated with cardiovascular disease than are larger LDL, the present results suggest that very high saturated fat intake may increase cardiovascular disease risk in phenotype B individuals. This trial was registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT00895141).

## Trial registration

Clinicaltrials.gov [NCT00895141](https://clinicaltrials.gov).

## Introduction

Current dietary guidelines aim at limiting saturated fat intake in large part because of its ability to increase LDL-cholesterol (LDL-C) levels and presumably, cardiovascular disease (CVD) risk. However, several recent meta-analyses and systematic reviews have concluded that saturated fat *per se* is not associated with greater CVD risk [1–3]. This may be due in part to differential effects of saturated fat on LDL subclass concentrations. Small and medium sized LDL particles have been shown to be more strongly associated with CVD outcomes than larger LDL [4–7]. We have previously reported results from a dietary intervention trial indicating that increased intake of total saturated fatty acids, particularly myristic (14:0) and palmitic (16:0) acids, correlated with increased plasma levels of larger LDL particles, but not with change in smaller LDL or apoB concentrations [8]. Moreover, in a subsequent clinical trial, we showed that in the context of reduced carbohydrate intake, the increase in LDL-C resulting from exchange of dietary saturated fat for monounsaturated fat was due primarily to higher concentrations of cholesterol-enriched larger LDL, without changes in smaller LDL or apoB [9]. Saturated fat also raises HDL-cholesterol (HDL-C) [10], which could potentially offset an atherogenic effect of raising LDL-C.

Atherogenic dyslipidemia is the most common dyslipidemia associated with obesity and insulin resistance and is characterized by elevated plasma triglycerides, low HDL-C, and increased levels of small, dense LDL particles [9]. Individuals with an abundance of small, dense LDL particles have been categorized as LDL phenotype B, while individuals with predominantly larger LDL particles have been categorized as LDL phenotype A [11]. The expression of LDL phenotype B is influenced by genetic predisposition, dietary macronutrient intake, and body weight [12]. High carbohydrate intake promotes increased plasma levels of liver-derived triglyceride-rich lipoproteins (VLDL) that can give rise to small, dense LDL particles and a conversion to or exacerbation of phenotype B [12].

The objective of the present study was to determine the effects of high saturated fat intake, primarily from dairy fat, on lipoprotein subclass concentrations in LDL phenotype B individuals. Based on our previous results [9] we hypothesized that the substitution of saturated fat for monounsaturated fat would preferentially increase concentrations of large, but not small, LDL particles, and that this would be accompanied by an increase in larger HDL particles.

## Materials and methods

The trial protocol ([S1 Protocol](#)) and CONSORT ([S1 CONSORT Checklist](#)) checklist are available as supporting information.

### Study population

Participants were recruited through internet advertisements and from our extensive database of previous study participants. Eligibility was based on the following criteria: male or postmenopausal female  $\geq 18$  y, non-smoking, LDL phenotype B as determined by ion mobility (see below), BMI 25–35 kg/m<sup>2</sup>, blood pressure < 150/90 mm Hg, fasting blood glucose < 7.0 mmol/L, plasma triglycerides < 5.65 mmol/L, and total-cholesterol (TC) and LDL-C  $\leq 95^{\text{th}}$  percentile for age and sex at screening. Participants had no history of diabetes, CVD, or other chronic disease, and were not taking dietary supplements, recreational drugs, drugs known to affect lipid metabolism, blood thinning agents, dietary supplements, or hormones. Premenopausal women were excluded because of their low prevalence of LDL phenotype B [13].

The study was conducted in free-living participants at the Cholesterol Research Center (Berkeley, CA). All participants provided written informed consent. The protocol was reviewed and approved by the Institutional Review Board of the University of California, San Francisco Benioff Children’s Hospital Oakland. The trial is registered at clinicaltrials.gov (NCT00895141).

**Study design and dietary intervention.** The study was conducted between April 2009 and December 2010. Participants consumed a baseline diet for 3 weeks followed by randomization to a low saturated fat (LSF) or high saturated fat (HSF) experimental diet for 3 weeks. They were randomly assigned to one of the two diets in randomly determined blocks of 2, 4, 6, or 8 individuals using a uniform random-number generator by a statistician who was not otherwise involved in recruitment or screening. Diet assignments were kept in sealed envelopes and assigned to the participant by the clinic staff 1–2d before starting the experimental diet. Investigators and staff assessing plasma outcomes were blinded to diet assignment, while clinic staff was not. Participants were not informed of their diet assignment, but due to the nature of the diets, were likely able to identify the experimental diet. Unblinding was performed after all data collection for all participants was completed. During the 3 wk baseline diet and 3 wk experimental diet, participants met with study staff weekly for dietary counseling, to receive study foods, and to be weighed. Body weight was stabilized by adjusting energy intake if needed. At the end of the baseline diet and experimental diet, participants visited the clinic for clinical and laboratory measurements.

Composition of the diets is shown in Table 1. The LSF and HSF diets were designed to have comparable amounts of carbohydrate, protein, and total fat with differences in saturated fat

**Table 1. Composition of baseline and experimental diets<sup>a</sup>.**

	Calculated <sup>b</sup>			Analyzed <sup>c</sup>		
	Baseline	LSF	HSF	Baseline	LSF	HSF
Carbohydrate, %E	55	35	35	nm	37	39
Protein, %E	15	25	25	nm	25	25
Fat, %E	30	40	40	nm	37	36
SFA	8	9	21	nm	9	18
MUFA	12	24	11	nm	19	9
PUFA	8	7	6	nm	7	6
Cholesterol, mg	219	374	385	nm	281	367

<sup>a</sup>Values given for a 12,557 kJ menu. %E, % energy; MUFA, monounsaturated fatty acids; nm, not measured; PUFA, polyunsaturated fatty acids SFA, saturated fatty acids.

<sup>b</sup>Calculated values include adjustments made after compositional analysis of individual SFA of dairy products and entrées performed during diet development.

<sup>c</sup>Compositional analysis of a complete week of foods and beverages.

doi:10.1371/journal.pone.0170664.t001

achieved by exchange for monounsaturated fat. Monounsaturated fat was chosen as the exchanged nutrient because this substitution has a smaller effect on LDL-C than does substituting either carbohydrate or polyunsaturated fat [10]. High vs. low/non-fat dairy products were the major sources of differences in saturated fatty acid content. Participants were provided with two standardized entrees and a snack per day and menus, shopping lists, and instructions for preparation of remaining food items. Diets were prescribed using a rotating 4-day menu. Menus were designed and entrees produced by the Bionutrition Unit of the University of California, San Francisco Clinical and Translation Sciences Institute (San Francisco, CA) using Pronutra software. Nutrient content of dairy products and daily menus was analyzed by compositional analysis (Covance Inc, Kalamazoo, MI).

## Laboratory measurements

Blood samples were collected after a 12–14 h overnight fast at screening and on two consecutive days after consumption of the baseline diet (day 20 and 21) and the randomized diet (day 41 and 42). Plasma TC, HDL-C, triglycerides (TG), and glucose were measured by enzymatic end-point measurements utilizing enzyme reagent kits on an Express 550 Plus analyzer (Ciba-Corning Diagnostics Corp., Oberlin, OH). TC, HDL-C, and TG were consistently in control as monitored by the Centers for Disease Control and Prevention-National Heart, Lung, and Blood Institute standardization program. LDL-C was calculated using the Friedewald equation [14]. ApoB and apoAI were measured by immunoturbidimetric assays (Express 550 Plus Analyzer: Bacton Assay Systems, San Marcos, CA) [15, 16]. LDL peak particle diameter, LDL phenotype, and lipoprotein particle concentrations were measured by ion mobility, which uses gas-phase differential electrophoretic macromolecular mobility to directly measure lipoprotein particle concentrations [17]. Individuals with LDL peak particle diameter below  $< 217.5\text{\AA}$  (midpoint of intermediate zone) were defined as LDL phenotype B, whereas those with LDL peak particle diameter  $\geq 217.5\text{\AA}$  were defined as LDL phenotype A [18]. Nondenaturing gradient gel electrophoresis with lipid staining of plasma was performed to confirm LDL ion mobility results as previously described [19]; in this procedure, cholesterol concentration for each LDL subclass was assessed by multiplying LDL cholesterol by the percentage of area under the curve defined for each subclass. Plasma cholesteryl ester transfer protein (CETP) activity was measured using a commercial assay (Roar Biomedical, New York, NY).

For measurements of hepatic lipase (HL) and lipoprotein lipase (LPL) activities, blood was collected after a bolus of intravenous heparin (60U/kg). HL activity was measured by selective inhibition of LPL with protamine sulfate as previously described [20]. LPL activity was calculated as the difference between lipase activities measured with and without protamine sulfate.

## Statistical procedures

Fasting TC, LDL-C, nonHDL-C, TG, HDL-C, and lipoprotein particle concentrations were calculated as the mean of two measurements. Participants' characteristics at randomization and at the end of the baseline diet are presented as mean  $\pm$  SD. The primary outcomes were differences in fasting plasma lipid and lipoprotein concentrations from baseline between the LSF and HSF diets. Secondary outcomes were differences in CETP, HL, and LPL activities from baseline between the diets. Analysis of covariance (ANCOVA) was used to test whether the mean 3-wk changes from baseline differed between the LSF and HSF diets when adjusted for sex, age, and baseline BMI. An N of 25 per group in a parallel design was estimated to yield a detectable difference of percent change from baseline between groups at 80% power and 5% significance (two-sided) of 22% for large LDL concentrations, 1.7% for LDL peak diameter, and 25% for large HDL concentrations. Based on previous results [8] we estimated that these

differences would be sufficient for detecting the expected effects of the low vs. high saturated fat diets. All p-values for diet-induced differences in 3-wk changes were determined based on differences in log transformed values. Log transformations were used to achieve greater consistency with normally distributed outcome measures. The differences in the logs were converted to percent change in the tables to be more easily interpreted. Spearman's correlation coefficients ( $\rho$ ) were used to evaluate the relationships between changes in lipoprotein measurements and enzyme activities. Changes in CETP and HL activity were added to the ANCOVA model described above to test for independent relationships with lipoprotein measurements. A p-value  $< 0.05$  was considered significant. Power calculations and tests of hypotheses were performed using JMP 9.0 (SAS) without adjustment for multiple hypothesis testing.

## Results

### Study participants

[Fig 1](#) shows the details of participant recruitment and enrollment. Forty-five men and eight postmenopausal women completed the study. Their baseline characteristics are shown in [Table 2](#). Note that despite screening study participants for LDL phenotype B, changes in phenotypes in the period between enrollment and completion of the baseline diet resulted in 11 participants who were phenotype A at randomization; these changes did not differ significantly between the two diet arms. Baseline BMI differed significantly between the LSF and HSF groups and was therefore used as a covariate in analyses of the diet effects. There were no other significant baseline differences between diet groups. There were also no significant changes in body weight during the dietary intervention in either the LSF ( $-0.3 \pm 0.2$  kg,  $p = 0.08$ ) or HSF ( $0.1 \pm 0.1$  kg,  $p = 0.71$ ) groups.

### Plasma lipids and lipoproteins


Compared to the LSF diet, the HSF diet significantly increased plasma TC, LDL-C, and apoB levels and marginally increased plasma TG ([Table 3](#)). There were no significant changes in HDL-C or apoAI.

Total, medium, and small LDL particle concentrations as measured by the ion mobility method were all increased after the HSF diet compared with the LSF diet ([Table 4](#)), although the p-values ( $p = 0.02$  to  $0.03$ ) were no longer significant after adjustment for multiple testing using the Bonferroni correction. There were no other significant differences in VLDL, intermediate density lipoprotein (IDL), LDL, or HDL subfraction concentrations or LDL peak particle diameter as measured by ion mobility after consuming the LSF vs. the HSF diets ([Table 4](#)), and no differences in the proportion of LDL phenotype or LDL phenotype conversions ( $p = 0.23$ , data not shown). Small LDL-C measured by gradient gel electrophoresis was significantly higher after the HSF compared to the LSF diet ( $p < 0.05$ , [S1 Fig](#)).

In these analyses, gender was included as a covariate and there were no gender by diet interactions for outcomes. When analyses were restricted to males, results for lipid and lipoprotein outcomes remained similar. However, the p-values increased slightly to become non-significant for medium, small, and total LDL concentrations ( $p = 0.10$ ,  $0.06$ , and  $p = 0.06$ , respectively) likely due to reduced sample size.

### Plasma activities of HL, LPL, and CETP

Both plasma HL and CETP activities were higher on the HSF diet compared to the LSF diet, but with borderline statistical significance ( $p = 0.04$  and  $0.05$ , respectively). There was no significant difference in LPL activity ([Table 4](#)).



**Fig 1. CONSORT flow diagram.**

doi:10.1371/journal.pone.0170664.g001

We explored the relationships of changes in CETP and lipase activities with changes in lipid and lipoprotein measurements. There were no significant diet interactions for these associations; thus the data for the two diets were combined for analysis (S1 Table). Changes in HL activity were correlated positively with changes in TG, TC, apoB, non-HDL-C, large and intermediate VLDL particles, and small and very small LDL, and negatively with LDL peak particle diameter. LPL activity changes were negatively correlated with changes in TG and large VLDL. Changes in CETP activity were significantly positively correlated with changes in TG, TC, apoB, non-HDL-C, large, medium, and small VLDL, IDL, and medium and small LDL.

Finally, we tested whether HL or CETP activities were significant covariates for the effect of increased saturated fat on small and medium LDL particles. In a model including age, gender, baseline BMI, saturated fat level, and changes in CETP and HL activity, changes in CETP

**Table 2. Participant characteristics at randomization (at the end of the baseline diet)<sup>a</sup>.**

	LSF	HSF	p-value <sup>b</sup>
M/F, N	21/6	24/2	0.13
Age, y	40 ± 12	46 ± 14	0.11
BMI, kg/m <sup>2</sup>	30.7 ± 2.4	28.9 ± 2.9	0.018
Waist, cm	103 ± 7	101 ± 7	0.21
TC, mmol/L	4.77 ± 1.01	4.51 ± 0.78	0.27
LDL-C, mmol/L	2.75 ± 0.73	2.72 ± 0.73	0.85
HDL-C, mmol/L	0.95 ± 0.21	0.93 ± 0.12	0.70
Non-HDL-C, mmol/L	3.83 ± 0.88	3.57 ± 0.73	0.26
TG <sup>c</sup> , mmol/L	2.46 ± 1.45	1.91 ± 0.97	0.07
ApoB, g/dl	9.2 ± 2.0	8.4 ± 1.6	0.11
ApoAI, g/dl	10.5 ± 15	10.2 ± 1.2	0.50
LDL phenotype, N	4A/23B	7A/19B	0.28
LDL peak diameter, Å	213.3 ± 4.2	215.0 ± 4.8	0.16
Total VLDL, nmol/L	167.5 ± 46.8	150.6 ± 43.1	0.18
Large VLDL, nmol/L	32.8 ± 12.8	27.2 ± 15.1	0.15
Medium VLDL, nmol/L	75.6 ± 23.8	67.5 ± 22.1	0.21
Small VLDL, nmol/L	59.1 ± 15.7	55.9 ± 11.4	0.40
IDL, nmol/L	135.9 ± 33.3	137.1 ± 31.8	0.89
Total LDL, nmol/L	1256 ± 229	1246 ± 314	0.90
Large LDL, nmol/L	444 ± 152	493 ± 173	0.28
Medium LDL, nmol/L	252 ± 79	255 ± 99	0.90
Small LDL, nmol/L	295 ± 104	262 ± 119	0.29
Very small LDL, nmol/L	265 ± 183	236 ± 171	0.56
Total HDL, nmol/L	4964 ± 1582	4880 ± 1041	0.82
Large HDL, nmol/L	793 ± 391	739 ± 168	0.93
Small HDL, nmol/L	4170 ± 1388	4141 ± 990	0.52
HL activity <sup>d</sup> , umol/ml/hr	22.7 ± 8.5	20.1 ± 6.9	0.26
LPL activity <sup>d</sup> , umol/ml/hr	5.2 ± 3.3	6.3 ± 2.5	0.21
CETP activity, nmol/ml/hr	21.7 ± 5.2	21.9 ± 5.2	0.88

<sup>a</sup>Mean ± SD. Apo, apolipoprotein; CETP, cholesteryl ester transfer protein; HL, hepatic lipase; HDL-C, HDL-cholesterol; HSF, high saturated fat diet; IDL, intermediate density lipoprotein; LPL, lipoprotein lipase; LDL-C, LDL cholesterol; LSF, low saturated fat diet; TC, total cholesterol; TG, triglycerides; VLDL, very low density lipoprotein.

<sup>b</sup>Student's t-test or Chi-squared test.

<sup>c</sup>Log transformed prior to analysis.

<sup>d</sup>N = 20/6 (M/F) for the LSF group and 21/2 (M/F) for the HSF group. Missing data were due to participants who did not complete a postheparin blood draw.

doi:10.1371/journal.pone.0170664.t002

activity remained significantly associated with small LDL ( $p = 0.009$ ) and medium LDL ( $p = 0.046$ ), while changes in HL activity ( $p = 0.57$  and  $0.46$ , respectively) and saturated fat intake ( $p = 0.12$  and  $0.09$ , respectively) were not.

## Discussion

Recent evidence has shown that although increased intake of saturated fatty acids can raise LDL-C when substituted for either carbohydrate or cis-unsaturated fatty acids [21], the substitution for carbohydrate is not associated with higher CVD risk [22–25]. We hypothesized that the dissociation of LDL-C change from effects on CVD risk may be due in part to a preferential effect of saturated fat on cholesterol-enriched large LDL particles, which are not as strongly

**Table 3. Percent changes from baseline in plasma lipid and lipoprotein concentrations in men and women with atherogenic dyslipidemia after 3 wk of consuming either a low or high saturated fat diet<sup>a</sup>.**

	LSF (N = 26)	HSF (N = 27)	P <sup>b</sup>
ΔTG	-11.5 (-23.4, 2.2)	9.8 (-5.2, 27.2)	0.06
ΔTC	-5.7 (-9.4, -1.8)	11.0 (6.5, 15.7)	<0.0001
ΔLDL-C	-8.7 (-15.4, -1.4)	16.7 (7.9, 26.2)	0.0001
ΔHDL-C	2.8 (-2.0, 7.8)	2.8 (-2.0, 7.9)	0.99
ΔNonHDL-C	-7.9 (-12.3, -3.3)	13.2 (7.7, 19.0)	<0.0001
ΔApoB	-6.8 (-11.7, -1.6)	9.5 (3.6, 15.7)	0.0003
ΔApoAI	-1.3 (-4.8, 2.2)	3.2 (-0.5, 7.1)	0.11

<sup>a</sup>percent change from baseline, mean (95% CI), adjusted for age, gender, and baseline BMI. Apo, apolipoprotein; HDL-C, HDL-cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol; TG, triglycerides.

<sup>b</sup>calculated from one-way ANCOVA using the difference in the log transformed values, adjusted for age, gender, and baseline BMI. Percent changes shown were derived by conversion from the differences in log transformed values.

doi:10.1371/journal.pone.0170664.t003

**Table 4. Percent changes from baseline in plasma lipoprotein subfractions and lipoprotein remodeling enzyme activities in men and women with atherogenic dyslipidemia after 3 wk of consuming either a low or high saturated fat diet<sup>a</sup>.**

	% Δ from baseline		
	LSF (N = 26)	HSF (N = 27)	P <sup>b</sup>
ΔTotal VLDL	-7.8 (-16.4, 1.6)	-1.3 (-10.7, 9.0)	0.37
ΔLarge VLDL	-13.3 (-26.3, 1.9)	0.0 (-15.3, 18.1)	0.26
ΔMedium VLDL	-6.9 (-16.3, 3.6)	-1.1 (-11.2, 10.3)	0.46
ΔSmall VLDL	-7.9 (-15.7, 0.7)	-0.7 (-9.3, 8.7)	0.28
ΔIDL	-8.3 (-15.7, -0.4)	3.5 (-5.0, 12.7)	0.06
ΔTotal LDL	-7.9 (-13.9, -1.5)	3.6 (-3.3, 11.0)	0.03
ΔLarge LDL	2.1 (-7.1, 12.2)	8.6 (-1.4, 19.6)	0.40
ΔMedium LDL	-7.3 (-15.7, 2.0)	8.8 (-1.3, 20.0)	0.03
ΔSmall LDL	-20.8 (-32.8, -6.7)	6.1 (-10.3, 25.6)	0.02
ΔVery small LDL	-19.3 (-31.1, -5.3)	-11.8 (-25.0, 3.7)	0.48
ΔLDL peak diameter	0.7 (0.1, 1.3)	0.2 (-0.5, 0.8)	0.27
ΔTotal HDL	0.6 (-9.2, 11.4)	6.3 (-4.3, 17.9)	0.49
ΔLarge HDL	-2.6 (-11.0, 6.7)	0.5 (-8.4, 10.2)	0.66
ΔSmall HDL	1.0 (-9.4, 12.5)	7.1 (-4.1, 19.6)	0.48
ΔHL activity <sup>c</sup>	-9.5 (-15.4, -3.2)	1.3 (-5.8, 8.8)	0.04
ΔLPL activity <sup>c</sup>	-15.7 (-38.2, 15.2)	-8.2 (-33.3, 26.2)	0.72
ΔCETP activity	-0.6 (-7.0, 6.2)	10.0 (2.7, 17.7)	0.05

<sup>a</sup>percent change from baseline, mean (95%CI), adjusted for age, gender, and baseline BMI. CETP, cholesteryl ester transfer protein; HL, hepatic lipase; IDL, intermediate density lipoprotein; LPL, lipoprotein lipase; VLDL, very low density lipoprotein.

<sup>b</sup>calculated from one-way ANCOVA using the difference in the log transformed values, adjusted for age, gender, and baseline BMI. Percent changes shown were derived by conversion from the differences in log transformed values.

doi:10.1371/journal.pone.0170664.t004



associated with CVD risk as are small and medium sized LDL particles [4–6]. In contrast, we and others have shown that higher carbohydrate intake promotes selective increases in levels of small LDL particles [9, 26–28]. In one of these studies, we found that in the context of reduced carbohydrate intake (26% E), increased intake of saturated fatty acids derived primarily from dairy fat preferentially raised large LDL without increasing small LDL or apoB concentrations [9]. This is consistent with results from other intervention studies [8, 29–33] and observational cohort studies [34–36] showing that diets high in saturated fat, derived in many cases from dairy sources, increased peak LDL particle diameter, and/or levels of larger LDL without raising levels of smaller LDL particles. Other studies however, have reported no significant effect of saturated fat on LDL particle size distribution [37–40]. In the present study, we found that with substitution of saturated fatty acids derived primarily from dairy foods for monounsaturated fatty acids, increased LDL-C was associated with increased apoB, and total, small, and medium-sized LDL particle concentrations. There were, however, no significant changes in large LDL, large HDL, or LDL peak diameter. We suggest a number of possible factors that may contribute, singly or in combination, to the discrepancy of these findings from those that we reported previously [9].

First, in the present trial, we enrolled men and postmenopausal women, who on screening expressed the small LDL particle phenotype B, whereas the majority of participants in our earlier study expressed large LDL phenotype A, and there were insufficient numbers of phenotype B individuals to permit testing the possibility of differential responses as a function of baseline LDL particle size phenotypes or other lipid and lipoprotein parameters. We are aware of one other report showing an effect of saturated fat on medium and smaller LDL particles. Gill, et al., showed a stepwise decrease in medium and smaller LDL particles with decreasing saturated fat intake (15%E to 11%E to 7%E) in 35 hypercholesterolemic individuals [41]. Thus is it possible that dyslipidemic individuals may be preferentially susceptible to saturated fat-induced increases in small and medium-sized LDL particles.

Second, the carbohydrate content of the diets in the present study was substantially greater than in our earlier trial (37–39% vs, 26%E). It may be that the effects of higher carbohydrate intake on pathways responsible for increased levels of smaller LDL particles create greater susceptibility to the effects of dietary saturated fat on small LDL particle concentrations. Further studies would be required to confirm such an interaction between dietary carbohydrate and saturated fat.

Finally, the saturated fatty acid content of the high saturated fat diet in the present study was 20% greater than in our previous study (18% vs 15%E), compared in both cases with 9% E. It is therefore possible that there is a threshold above which saturated fat induces metabolic changes resulting in increased levels of smaller LDL particles. Saturated fat is thought to increase LDL-C primarily through down-regulation of hepatic LDL receptor activity, leading to reduced clearance of LDL particles [42, 43]. While smaller LDL particles are less dependent on LDL receptor-mediated uptake than larger LDL [44], it may be that the very high level of saturated fat in the present study suppresses LDL receptor activity sufficiently so as to reduce plasma clearance of smaller LDL in individuals with the small LDL phenotype. It is also conceivable that the high levels of saturated fat studied here might increase direct hepatic secretion of small LDL or their precursors, or perhaps suppress non-LDL receptor pathways responsible for clearance of smaller LDL particles. Consistent with the possibility of a threshold effect of very high dietary saturated fatty acid intake on levels of smaller vs. larger LDL particles is the observation from the Framingham cohort [36] that LDL peak diameter was larger in individuals in the 25–75<sup>th</sup> percentile of saturated fat intake (mean: 12.5%E), compared to those in either the < 25<sup>th</sup> percentile (mean: 9%E) or > 75<sup>th</sup> percentile (mean: 17%E).

We performed exploratory analyses using data from both diet arms to test for relationships of changes in activities of factors involved in lipoprotein catabolism and remodeling with changes in plasma lipids and lipoproteins. As expected, changes in LPL were inversely correlated with changes in TG and TG-rich VLDL particles. Positive correlations of change in hepatic lipase activity with changes in larger VLDL particles and smaller LDL particles, are consistent with previous reports [45, 46] and with the role of hepatic lipase in generating small, dense LDL [47]. A novel finding in the present study was the positive correlation of changes in CETP activity with changes in all of the apoB-containing lipoprotein particle fractions with the exception of large and very small LDL.

Although mean changes in both HL and CETP from the baseline diet showed only marginally significant differences between the HSF and LSF diets, inclusion of both of these activities in a model also containing diet assignment indicated that change in CETP but not HL activity remained significantly associated with change in small LDL particle concentration, suggesting that the increase in CETP may have contributed in part to the effect of high saturated fat intake on these particles, and that the HL association was dependent on this CETP effect. This possibility is consistent with previous studies demonstrating increases in CETP mass or activity with very high saturated fat intakes ( $\geq 19\%$ E) [48–50], and positive correlations between changes in CETP activity and changes in total- and LDL-cholesterol [48, 49]. Moreover, in monkeys fed a high saturated fat diet, increased CETP activity was associated with reduced LDL receptor activity [51].

Strengths of our study include a lack of confounding by weight loss, detailed lipoprotein subclass measurements using two different analytical methods, and a saturated fat-induced increase in LDL-C consistent with predictive formulas [21] (data not shown), indicative of good dietary adherence. One limitation of the study is that since all participants were LDL phenotype B when enrolled, we are unable to determine whether the results are specific to individuals with this metabolic trait. Although some individuals converted to LDL phenotype A after the baseline diet, there were insufficient numbers to formally evaluate potential differences in response between the two baseline LDL phenotypes. In addition, the dietary intervention was short-term and may not reflect long-term intake of high saturated fat diets. Finally, the increase in saturated fat content on the HSF diet was primarily derived from dairy foods, and thus the findings may not be applicable to other sources of saturated fat.

In conclusion, we found that the increase in LDL-C resulting from very high saturated fat intake in individuals with a preponderance of small LDL was associated with an increase in apoB, and total, medium-sized, and small LDL particles. These results, in conjunction with previous studies, suggest that saturated fat may have heterogeneous effects on levels of atherogenic LDL particles that may depend on the amount of saturated fat consumed, the dietary context, particularly concomitant carbohydrate intake, and/or predisposition to atherogenic dyslipidemia.

## Supporting information

**S1 CONSORT Checklist.** CONSORT checklist.

(PDF)

**S1 Dataset.** Minimal data set for results presented.

(XLSX)

**S1 Fig.** Changes in LDL subfractions as measured by gradient gel electrophoresis after 3 wk of consuming either a low saturated fat (LSF, N = 26) or high saturated fat (HSF, N = 27) diet. Concentration of each LDL subclass was determined by multiplying the LDL

cholesterol with the percentage of area under the curve defined for each subclass. \*Different from LSF diet,  $p < 0.05$ .

(TIF)

### **S1 Protocol. Trial protocol.**

(PDF)

### **S1 Table. Spearman's rho correlations of change in enzyme activities and change in lipid and lipoproteins.**

(PDF)

## **Author contributions**

**Conceptualization:** RMK SC.

**Formal analysis:** RMK SC PTW.

**Funding acquisition:** RMK.

**Investigation:** SC RMK.

**Methodology:** RMK SC.

**Supervision:** RMK.

**Writing – original draft:** SC PTW RMK.

**Writing – review & editing:** SC PTW RMK.

## **References**

1. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med.* 2014 Mar 18; 160(6):398–406. doi: [10.7326/M13-1788](https://doi.org/10.7326/M13-1788) PMID: [24723079](https://pubmed.ncbi.nlm.nih.gov/24723079/)
2. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med.* 2009 Apr 13; 169(7):659–69. Epub 2009/04/15. eng. doi: [10.1001/archinternmed.2009.38](https://doi.org/10.1001/archinternmed.2009.38) PMID: [19364995](https://pubmed.ncbi.nlm.nih.gov/19364995/)
3. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr.* 2010 Mar; 91(3):535–46. Epub 2010/01/15. eng. doi: [10.3945/ajcn.2009.27725](https://doi.org/10.3945/ajcn.2009.27725) PMID: [20071648](https://pubmed.ncbi.nlm.nih.gov/20071648/)
4. Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. *Arterioscler Thromb Vasc Biol.* 2009 Nov; 29(11):1975–80. PMC2772123. Epub 2009/09/05. eng. doi: [10.1161/ATVBAHA.109.190405](https://doi.org/10.1161/ATVBAHA.109.190405) PMID: [19729614](https://pubmed.ncbi.nlm.nih.gov/19729614/)
5. Williams PT, Zhao XQ, Marcovina SM, Otvos JD, Brown BG, Krauss RM. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. *Atherosclerosis.* 2014 Apr; 233(2):713–20. doi: [10.1016/j.atherosclerosis.2014.01.034](https://doi.org/10.1016/j.atherosclerosis.2014.01.034) PMID: [24603218](https://pubmed.ncbi.nlm.nih.gov/24603218/)
6. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. *Arterioscler Thromb Vasc Biol.* 2005 Mar; 25(3):553–9. Epub 2004/12/25. eng. doi: [10.1161/01.ATV.0000154144.73236.f4](https://doi.org/10.1161/01.ATV.0000154144.73236.f4) PMID: [15618542](https://pubmed.ncbi.nlm.nih.gov/15618542/)
7. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation.* 2009 Feb 24; 119(7):931–9. Epub 2009/02/11. eng. doi: [10.1161/CIRCULATIONAHA.108.816181](https://doi.org/10.1161/CIRCULATIONAHA.108.816181) PMID: [19204302](https://pubmed.ncbi.nlm.nih.gov/19204302/)
8. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. *Am J Clin Nutr.* 1998 May; 67(5):828–36. Epub 1998/05/16. eng. PMID: [9583838](https://pubmed.ncbi.nlm.nih.gov/9583838/)

9. Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. *Am J Clin Nutr.* 2006 May; 83(5):1025–31; quiz 205. Epub 2006/05/11. eng. PMID: [16685042](#)
10. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. *Arterioscler Thromb.* 1992 Aug; 12(8):911–9. Epub 1992/08/01. eng. PMID: [1386252](#)
11. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation.* 1990 Aug; 82(2):495–506. Epub 1990/08/01. eng. PMID: [2372896](#)
12. Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. *Arterioscler Thromb Vasc Biol.* 2005 Nov; 25(11):2265–72. Epub 2005/09/17. eng. doi: [10.1161/01.ATV.0000186365.73973.f0](#) PMID: [16166563](#)
13. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. *Am J Hum Genet.* 1988 Dec; 43(6):838–46. PMID: [3195585](#)
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972 Jun; 18(6):499–502. Epub 1972/06/01. eng. PMID: [4337382](#)
15. Smith SJ, Cooper GR, Henderson LO, Hannon WH. An international collaborative study on standardization of apolipoproteins A-I and B. Part I. Evaluation of a lyophilized candidate reference and calibration material. *Clin Chem.* 1987 Dec; 33(12):2240–9. PMID: [3121214](#)
16. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. *Clin Chem.* 1986 Jun; 32(6):957–61. PMID: [3085982](#)
17. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. *Clin Chem.* 2008 Aug; 54(8):1307–16. Epub 2008/06/03. eng. doi: [10.1373/clinchem.2007.100586](#) PMID: [18515257](#)
18. Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. *Atherosclerosis.* 2012 Feb; 220(2):470–6. doi: [10.1016/j.atherosclerosis.2011.10.029](#) PMID: [22169113](#)
19. Siri-Tarino PW, Woods AC, Bray GA, Krauss RM. Reversal of small, dense LDL subclass phenotype by weight loss is associated with impaired fat oxidation. *Obesity (Silver Spring).* 2010 Jan; 19(1):61–8. Epub 2010/06/19. eng.
20. Mangravite LM, Chiu S, Wojnoonski K, Rawlings RS, Bergeron N, Krauss RM. Changes in atherogenic dyslipidemia induced by carbohydrate restriction in men are dependent on dietary protein source. *J Nutr.* 2011 Dec; 141(12):2180–5. doi: [10.3945/jn.111.139477](#) PMID: [22031660](#)
21. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr.* 2003 May; 77(5):1146–55. Epub 2003/04/30. eng. PMID: [12716665](#)
22. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. *Curr Atheroscler Rep.* 2010 Nov; 12(6):384–90. Epub 2010/08/17. eng. doi: [10.1007/s11883-010-0131-6](#) PMID: [20711693](#)
23. Jakobsen MU, Dethlefsen C, Joensen AM, Stegger J, Tjonneland A, Schmidt EB, et al. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. *Am J Clin Nutr.* 2010 Jun; 91(6):1764–8. Epub 2010/04/09. eng. doi: [10.3945/ajcn.2009.29099](#) PMID: [20375186](#)
24. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Balter K, Fraser GE, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. *Am J Clin Nutr.* 2009 May; 89(5):1425–32. Epub 2009/02/13. eng. doi: [10.3945/ajcn.2008.27124](#) PMID: [19211817](#)
25. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med.* 2010; 7(3):e1000252. Epub 2010/03/31. eng. doi: [10.1371/journal.pmed.1000252](#) PMID: [20351774](#)
26. Krauss RM. Dietary and genetic effects on low-density lipoprotein heterogeneity. *Annu Rev Nutr.* 2001; 21:283–95. Epub 2001/05/26. eng. doi: [10.1146/annurev.nutr.21.1.283](#) PMID: [11375438](#)
27. Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. *Metabolism.* 2012 Jan; 61(1):76–83. doi: [10.1016/j.metabol.2011.06.002](#) PMID: [21816443](#)
28. Westman EC, Yancy WS Jr., Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. *International journal of cardiology.* 2006 Jun 16; 110(2):212–6. doi: [10.1016/j.ijcard.2005.08.034](#) PMID: [16297472](#)

29. Kratz M, Gulbahce E, von Eckardstein A, Cullen P, Cignarella A, Assmann G, et al. Dietary mono- and polyunsaturated fatty acids similarly affect LDL size in healthy men and women. *J Nutr.* 2002 Apr; 132(4):715–8. Epub 2002/04/02. eng. PMID: [11925466](#)
30. Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. *Am J Clin Nutr.* 2003 Sep; 78(3):370–5. Epub 2003/08/26. eng. PMID: [12936917](#)
31. Eger S, Kratz M, Kannenberg F, Fobker M, Wahrburg U. Effects of high-fat and low-fat diets rich in monounsaturated fatty acids on serum lipids, LDL size and indices of lipid peroxidation in healthy non-obese men and women when consumed under controlled conditions. *Eur J Nutr.* 2011 Feb; 50(1):71–9. doi: [10.1007/s00394-010-0116-9](#) PMID: [20521076](#)
32. Wang L, Bordi PL, Fleming JA, Hill AM, Kris-Etherton PM. Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial. *Journal of the American Heart Association.* 2015 Jan; 4(1):e001355. doi: [10.1161/JAHA.114.001355](#) PMID: [25567051](#)
33. Chiu S, Bergeron N, Williams PT, Bray GA, Sutherland B, Krauss RM. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. *Am J Clin Nutr.* 2016 Feb; 103(2):341–7. doi: [10.3945/ajcn.115.123281](#) PMID: [26718414](#)
34. Sjogren P, Rosell M, Skoglund-Andersson C, Zdravkovic S, Vessby B, de Faire U, et al. Milk-derived fatty acids are associated with a more favorable LDL particle size distribution in healthy men. *J Nutr.* 2004 Jul; 134(7):1729–35. Epub 2004/07/01. eng. PMID: [15226461](#)
35. Sonestedt E, Wirfalt E, Wallstrom P, Gullberg B, Drake I, Hlebowicz J, et al. High disaccharide intake associates with atherogenic lipoprotein profile. *Br J Nutr.* 2012 Apr; 107(7):1062–9. Epub 2011/10/21. eng. doi: [10.1017/S0007114511003783](#) PMID: [22011476](#)
36. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, et al. LDL particle size distribution. Results from the Framingham Offspring Study. *Arterioscler Thromb.* 1992 Dec; 12(12):1410–9. PMID: [1450174](#)
37. Rivelles AA, Maffettone A, Vessby B, Uusitupa M, Hermansen K, Berglund L, et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. *Atherosclerosis.* 2003 Mar; 167(1):149–58. Epub 2003/03/06. eng. PMID: [12618280](#)
38. Thijssen MA, Mensink RP. Small differences in the effects of stearic acid, oleic acid, and linoleic acid on the serum lipoprotein profile of humans. *Am J Clin Nutr.* 2005 Sep; 82(3):510–6. Epub 2005/09/13. eng. PMID: [16155261](#)
39. Jebb SA, Lovegrove JA, Griffin BA, Frost GS, Moore CS, Chatfield MD, et al. Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. *Am J Clin Nutr.* 2010 Oct; 92(4):748–58. Epub 2010/08/27. eng. doi: [10.3945/ajcn.2009.29096](#) PMID: [20739418](#)
40. Forsythe CE, Phinney SD, Feinman RD, Volk BM, Freidenreich D, Quann E, et al. Limited effect of dietary saturated fat on plasma saturated fat in the context of a low carbohydrate diet. *Lipids.* 2010 Oct; 45(10):947–62. Epub 2010/09/08. eng. doi: [10.1007/s11745-010-3467-3](#) PMID: [20820932](#)
41. Gill JM, Brown JC, Caslake MJ, Wright DM, Cooney J, Bedford D, et al. Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. *Am J Clin Nutr.* 2003 Jul; 78(1):47–56. PMID: [12816770](#)
42. Bennett AJ, Billett MA, Salter AM, Mangiapane EH, Bruce JS, Anderton KL, et al. Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and plasma lipoprotein concentrations by defined dietary fats. Comparison of trimyrustin, tripalmitin, tristearin and triolein. *Biochem J.* 1995 Oct 1; 311 (Pt 1):167–73. Epub 1995/10/01. eng.
43. Woollett LA, Spady DK, Dietschy JM. Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. *J Lipid Res.* 1992 Jan; 33(1):77–88. Epub 1992/01/01. eng. PMID: [1552235](#)
44. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res.* 2002 Sep; 43(9):1363–79. Epub 2002/09/18. eng. PMID: [12235168](#)
45. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. *Arterioscler Thromb.* 1993 Feb; 13(2):147–53. Epub 1993/02/01. eng. PMID: [8427851](#)
46. Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. *J Lipid Res.* 1995 Mar; 36(3):462–72. Epub 1995/03/01. eng. PMID: [7775858](#)

47. Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. *Arterioscler Thromb Vasc Biol.* 2004 Jan; 24(1):141–6. doi: [10.1161/01.ATV.0000107027.73816.ce](https://doi.org/10.1161/01.ATV.0000107027.73816.ce) PMID: [14615390](https://pubmed.ncbi.nlm.nih.gov/14615390/)
48. Groener JE, van Ramshorst EM, Katan MB, Mensink RP, van Tol A. Diet-induced alteration in the activity of plasma lipid transfer protein in normolipidemic human subjects. *Atherosclerosis.* 1991 Apr; 87(2–3):221–6. Epub 1991/04/01. eng. PMID: [1854368](https://pubmed.ncbi.nlm.nih.gov/1854368/)
49. Jansen S, Lopez-Miranda J, Castro P, Lopez-Segura F, Marin C, Ordovas JM, et al. Low-fat and high-monounsaturated fatty acid diets decrease plasma cholesterol ester transfer protein concentrations in young, healthy, normolipemic men. *Am J Clin Nutr.* 2000 Jul; 72(1):36–41. Epub 2000/06/29. eng. PMID: [10871558](https://pubmed.ncbi.nlm.nih.gov/10871558/)
50. Lagrost L, Mensink RP, Guyard-Dangremont V, Temme EH, Desrumaux C, Athias A, et al. Variations in serum cholesteryl ester transfer and phospholipid transfer activities in healthy women and men consuming diets enriched in lauric, palmitic or oleic acids. *Atherosclerosis.* 1999 Feb; 142(2):395–402. Epub 1999/02/25. eng. PMID: [10030391](https://pubmed.ncbi.nlm.nih.gov/10030391/)
51. Fusegawa Y, Kelley KL, Sawyer JK, Shah RN, Rudel LL. Influence of dietary fatty acid composition on the relationship between CETP activity and plasma lipoproteins in monkeys. *J Lipid Res.* 2001 Nov; 42(11):1849–57. Epub 2001/11/21. eng. PMID: [11714854](https://pubmed.ncbi.nlm.nih.gov/11714854/)